Opiant Pharmaceuticals (NASDAQ: OPNT) and Strongbridge Biopharma PLC (NASDAQ:SBBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Opiant Pharmaceuticals and Strongbridge Biopharma PLC, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Strongbridge Biopharma PLC 0 0 3 0 3.00

Strongbridge Biopharma PLC has a consensus target price of $13.33, suggesting a potential upside of 118.58%. Given Strongbridge Biopharma PLC’s higher probable upside, analysts clearly believe Strongbridge Biopharma PLC is more favorable than Opiant Pharmaceuticals.

Volatility & Risk

Opiant Pharmaceuticals has a beta of -0.97, suggesting that its share price is 197% less volatile than the S&P 500. Comparatively, Strongbridge Biopharma PLC has a beta of 2.71, suggesting that its share price is 171% more volatile than the S&P 500.

Institutional & Insider Ownership

63.7% of Strongbridge Biopharma PLC shares are held by institutional investors. 63.8% of Opiant Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Opiant Pharmaceuticals and Strongbridge Biopharma PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 38.89% 5,686.82% 87.49%
Strongbridge Biopharma PLC N/A -83.83% -34.77%

Earnings & Valuation

This table compares Opiant Pharmaceuticals and Strongbridge Biopharma PLC’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million 4.67 $5.99 million $2.54 13.58
Strongbridge Biopharma PLC $1.53 million 140.88 -$39.43 million ($2.78) -2.19

Opiant Pharmaceuticals has higher revenue and earnings than Strongbridge Biopharma PLC. Strongbridge Biopharma PLC is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Opiant Pharmaceuticals beats Strongbridge Biopharma PLC on 7 of the 12 factors compared between the two stocks.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Receive News & Stock Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.